EXCEMED adheres to guidelines of the European Accreditation Council for Continuing Medical Education (EACCME®) and all other professional organizations, as applicable, which state that programmes awarding continuing education credits must be balanced, independent, objective, and scientifically rigorous. Investigative and other uses for pharmaceutical agents, medical devices, and other products (other than those uses indicated in approved product labeling/package insert for the product) may be presented in the programme (which may reflect clinical experience, the professional literature or other clinical sources known to the presenter). We ask all presenters to provide participants with information about relationships with pharmaceutical or medical equipment companies that may have relevance to their lectures. This policy is not intended to exclude faculty who have relationships with such companies; it is only intended to inform participants of any potential conflicts so that participants may form their own judgements, based on full disclosure of the facts. Further, all opinions and recommendations presented during the programme and all programme-related materials neither imply an endorsement nor a recommendation on the part of EXCEMED. All presentations represent solely the independent views of the presenters/authors.

The following faculty provided information regarding significant commercial relationships and/or discussions of investigational or non-EMEA/FDA approved (off-label) uses of drugs:

Antonio Capalbo Declared receipt of grants for fertility innovation.

Tim Child Declared receipts of grants and contracts from MRC. He is member of a company advisory board, board of directors or other similar group: Repin B.V.

Renato Fanchin Declared receipt of honoraria and consultation fees from Merck Serono.

Robert Fischer Declared no potential conflict of interest.

Roy Homburg Declared no potential conflict of interest.

Antonio La Marca Declared receipt of honoraria or consultation fees from Roche, MSD, Ferring, IBSA, Merck Serono.

Stuart Lavery Declared receipt of honoraria or consultation fees from Ferring and Merck Serono. He declared also receipt of grants and research support from Imperial College and Merck Serono.

The following faculty have provided no information regarding significant relationship with commercial supporters and/or discussion of investigational or non-EMEA/FDA approved (off-label) uses of drugs as of 25 August 2014.

Peter Humaidan

Sesh Kamal Sunkara